Our team
Scientific Advisory Board
Dr. Toni Pérez
Chairman, Clinical Advisory Board


José Miguel Lizcano, PhD
Chairman, Scientific Advisory Board


Dr. Pere Gascón


Dr. Jordi Rodón


Miguel F. Segura, PhD


Dra. Soledad Gallego


Dra. Ana Oaknin
After working in several hospitals, she currently occupies the position of "Head of Gynecologic Cancer Program at Vall d'Hebron Institute of Oncology" (VHIO). Her professional career is mainly based on clinical research, being the principal investigator of numerous Phase I, II and III clinical studies, both national and international. She is a member of groups such as SEOM, GEICO, ESMO, GCIG, ASCO, GOG and NCI.


Antoni Martinez-Tobed, PhD
He worked for 27 years at the research center of Almirall, SA, as head of the pharmacokinetics and metabolism department, director of preclinical development and preclinical scientific director.
Antoni has a comprehensive knowledge of preclinical drug development, including bioanalysis, pharmacokinetics, metabolism, toxicology and clinical pharmacology, gained through over 35 years of experience in pharmaceutical companies and CROs.
He has a wide experience in assessment of preclinical and clinical pharmacology dossiers in development phases, and contributed to marketing approval of several new drugs in Europe, USA and Japan.


Jordi Espadaler, PhD
Research Advisor and co-Founder
Jordi obtained a BSc/MSc degree in biochemistry from the Autonomous University of Barcelona and also a PhD degree (Doctorate Extraordinary Award) from the same University. During his doctorate, Dr. Espadaler collaborated actively with Prof. Andrej Săli, a world-recognized expert in structural biology, and did several stays in his laboratory, both at the Rockefeller University (New York) and the University of California San Francisco.
In 2006 he joined AB-Biotics SA when the company had just two employees and helped it to grow from a small start-up to a publicly traded company with around 40 employees.
Jordi has published 10 articles in peer-reviewed journals and 3 patents (two of them are international patents), and is also a visiting professor since 2008 at the Master of Bioengineering of the Institut Químic de Sarrià (Ramon Llull University, Barcelona).
In 2009 Jordi cofounded Ability Pharmaceuticals, SL to become its Vice-President, Drug Discovery in September 2009.


LATEST NEWS
News
Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + infoNews
Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + infoNews
AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + infoNews
Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + infoNews
Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + infoNews
At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + infoNews
AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + infoNews
AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + infoNews
Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info